{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:05:09Z","timestamp":1791389109704,"version":"4.3.3"},"reference-count":35,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"unspecified","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2026,1,26]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III EXPLORER-HCM trial has demonstrated that the novel cardiac myosin inhibitor Mavacamten can significantly improve patients\u2019 symptomatic and functional status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to evaluate the cost-effectiveness of the MBC regimen (Mavacamten plus a \u03b2-blocker or a calcium-channel blocker) versus the PBC regimen (placebo plus a \u03b2-blocker or a calcium-channel blocker) for treating Obstructive Hypertrophic Cardiomyopathy from the perspective of the Chinese Healthcare System.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Markov model was constructed using data from the EXPLORER-HCM clinical trial. Cost and utility inputs were sourced from public databases and published literature. Total costs, life-years (LY), quality-adjusted life years (QALY) and the incremental cost-effectiveness ratio (ICER) were assessed. One-way deterministic sensitivity analysis and probabilistic sensitivity analysis were conducted to examine the robustness of the model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with the PBC regimen, Mavacamten treatment yielded an ICER of US$50 587.23\/QALY. Its incremental cost was US$106 221.41, providing 2.1 additional QALY and 3.15 LY. Sensitivity analyses indicated that the drug price was the key driver influencing changes in the ICER value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study confirms that Mavacamten provides substantial health benefits to patients, but its relatively high ICER exceeds the commonly accepted willingness to pay.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/openhrt-2025-003914","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:50:24Z","timestamp":1771606224000},"page":"e003914","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness analysis of mavacamten for obstructive hypertrophic cardiomyopathy: a perspective from the Chinese healthcare system"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3458-2009","authenticated-orcid":false,"given":"Jialing","family":"Qian","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Jiang","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"2026090204551463000_13.1.e003914.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042339"},{"key":"2026090204551463000_13.1.e003914.2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-025-00643-0","article-title":"Hypertrophic cardiomyopathy","volume":"11","author":"Argir\u00f2","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"2026090204551463000_13.1.e003914.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021332"},{"key":"2026090204551463000_13.1.e003914.4","first-page":"1015","article-title":"Chinese Society of Cardiology, Chinese Adult Hypertrophic Cardiomyopathy Diagnosis and Treatment Guideline Writing Group, Editorial Board of Chinese Journal of Cardiology. Chinese Guidelines for the Diagnosis and Treatment of Adult Hypertrophic Cardiomyopathy","volume":"45","year":"2017","journal-title":"Chinese Journal of Cardiology"},{"key":"2026090204551463000_13.1.e003914.5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s43044-024-00532-z","article-title":"Prognostic value of quality of life and functional status in patients with heart failure: a systematic review and meta-analysis","volume":"76","author":"Ali","year":"2024","journal-title":"Egypt Heart J"},{"key":"2026090204551463000_13.1.e003914.6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2217\/fca-2023-0056","article-title":"Obstructive hypertrophic cardiomyopathy: a review of new therapies","volume":"19","author":"Mehra","year":"2023","journal-title":"Future Cardiol"},{"key":"2026090204551463000_13.1.e003914.7","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.541"},{"key":"2026090204551463000_13.1.e003914.8","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/ehf2.14272","article-title":"Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients?","volume":"10","author":"Achim","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026090204551463000_13.1.e003914.9","first-page":"2324","article-title":"AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"83","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026090204551463000_13.1.e003914.10","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.jtcvs.2020.10.062","article-title":"Early septal reduction therapy for patients with obstructive hypertrophic cardiomyopathy","volume":"164","author":"Cui","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026090204551463000_13.1.e003914.11","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/ehjqcco\/qcae092","article-title":"Loss of quality of life and increased societal costs in patients with hypertrophic cardiomyopathy: the AFFECT-HCM study","volume":"11","author":"Schoonvelde","year":"2025","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026090204551463000_13.1.e003914.12","doi-asserted-by":"crossref","DOI":"10.3390\/biom15081098","article-title":"Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: Clinical Trials and Future Challenges","volume":"15","author":"Kukowka","year":"2025","journal-title":"Biomolecules"},{"key":"2026090204551463000_13.1.e003914.13","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Spertus","year":"2021","journal-title":"The Lancet"},{"key":"2026090204551463000_13.1.e003914.14","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","article-title":"Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial","volume":"8","author":"Tian","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026090204551463000_13.1.e003914.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2023.09.028"},{"key":"2026090204551463000_13.1.e003914.16","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.2147\/IJN.S323831","article-title":"Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment","volume":"16","author":"Milewska","year":"2021","journal-title":"Int J Nanomedicine"},{"key":"2026090204551463000_13.1.e003914.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260247","article-title":"Using allocative efficiency analysis to inform health benefits package design for progressing towards Universal Health Coverage: Proof-of-concept studies in countries seeking decision support","volume":"16","author":"Fraser-Hurt","year":"2021","journal-title":"PLoS One"},{"key":"2026090204551463000_13.1.e003914.18","unstructured":"Cost-effectiveness in health and medicine. Oxford academic. Available: https:\/\/academic.oup.com\/book\/12265 [Accessed 18 Jan 2026]."},{"key":"2026090204551463000_13.1.e003914.19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-067975","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022","volume":"376","author":"Husereau","year":"2022","journal-title":"BMJ"},{"key":"2026090204551463000_13.1.e003914.20","doi-asserted-by":"crossref","unstructured":"Cott\u00e9 F-E , Hurst M , Akarkoub S , et al . Cost-effectiveness of Mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy using a French healthcare perspective. Eur J Health Econ 2025. doi:10.1007\/s10198-025-01808-0","DOI":"10.1007\/s10198-025-01808-0"},{"key":"2026090204551463000_13.1.e003914.21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.clinthera.2021.11.006","article-title":"Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit","volume":"44","author":"Desai","year":"2022","journal-title":"Clin Ther"},{"key":"2026090204551463000_13.1.e003914.22","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/13696998.2023.2277076","article-title":"Cardiovascular outcomes by time-varying New York Heart Association class among patients with obstructive hypertrophic cardiomyopathy: a retrospective cohort study","volume":"26","author":"Wang","year":"2023","journal-title":"J Med Econ"},{"key":"2026090204551463000_13.1.e003914.23","unstructured":"China population census yearbook -2020. Available: https:\/\/www.stats.gov.cn\/sj\/pcsj\/rkpc\/7rp\/zk\/indexch.htm [Accessed 18 Jan 2026]."},{"key":"2026090204551463000_13.1.e003914.24","unstructured":"Patient characteristic, treatment pattern, and healthcare resource utilization of obstructive hypertrophic cardiomyopathy (HCM) in China on a cardiologist survey. ISPOR | International Society For Pharmacoeconomics and Outcomes Research. Available: https:\/\/www.ispor.org\/heor-resources\/presentations-database\/presentation\/euro2024-4013\/142985 [Accessed 14 Nov 2025]."},{"key":"2026090204551463000_13.1.e003914.25","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.rec.2025.04.004","article-title":"Clinical management and healthcare resource utilization among patients with obstructive hypertrophic cardiomyopathy in Spain: a real-world study","volume":"78","author":"Barriales-Villa","year":"2025","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"},{"key":"2026090204551463000_13.1.e003914.26","unstructured":"Yaozhi.com- biopharma & healthcare industry big data service and empowerment platform. Available: https:\/\/www.yaozh.com\/ [Accessed 23 Nov 2025]."},{"key":"2026090204551463000_13.1.e003914.27","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.clinthera.2025.06.011","article-title":"Cost-Effectiveness of Antiarrhythmic Drugs for Treating Paroxysmal or Persistent Atrial Fibrillation in China: An Economic Evaluation","volume":"47","author":"Li","year":"2025","journal-title":"Clin Ther"},{"key":"2026090204551463000_13.1.e003914.28","unstructured":"CPI inflation calculator. Bureau of Labor Statistics. Available: https:\/\/www.bls.gov\/data\/inflation_calculator.htm [Accessed 20 Jan 2026]."},{"key":"2026090204551463000_13.1.e003914.29","unstructured":"ISPOR - quantifying health related quality of life benefits from patients treated with mavacamten for obstructive hypertrophic cardiomyopathy (HCM) in China based on the explorer-cn trial. Available: https:\/\/www.ispor.org\/heor-resources\/presentations-database\/presentation\/euro2024-4015\/143418 [Accessed 18 Jan 2026]."},{"key":"2026090204551463000_13.1.e003914.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1405158"},{"key":"2026090204551463000_13.1.e003914.31","unstructured":"Announcement by the chinese pharmaceutical association on the release of the group standard \u201cChina guidelines for pharmacoeconomic evaluation 2020\u201d - chinese pharmaceutical association. Available: https:\/\/www.cpa.org.cn\/index.php?do=info&cid=75553 [Accessed 24 Nov 2025]."},{"key":"2026090204551463000_13.1.e003914.32","doi-asserted-by":"crossref","unstructured":"Pradelli L , Povero M , B\u00fcrkle H , et al . Propofol or benzodiazepines for short- and long-term sedation in intensive care units? An economic evaluation based on meta-analytic results. Clin Outcomes Res CEOR 2017.","DOI":"10.2147\/CEOR.S136720"},{"key":"2026090204551463000_13.1.e003914.33","doi-asserted-by":"crossref","first-page":"1122731","DOI":"10.3389\/fmed.2023.1122731","article-title":"Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China","volume":"10","author":"Dai","year":"2023","journal-title":"Front Med"},{"key":"2026090204551463000_13.1.e003914.34","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad637"},{"key":"2026090204551463000_13.1.e003914.35","unstructured":"GVS report mavacamten (camzyos) - Zorginstituut Netherlands. Declarations a.Ethics approval and consent to participate; 2024."}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2025-003914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:55:29Z","timestamp":1788350129000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2025-003914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,20]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/openhrt-2025-003914"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2025-003914","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}